No Ebola case detected in the country so far; experts say a robust preparedness plan to fight the virus missing.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
A factor which would be key to Scotch consumers is the new currency an independent Scotland would go for .
Through the UB Group, Mallya holds 21.98 per cent stake in MCF.
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.
The Ministry of Science and Technology has approached about a dozen well-known scientists from across the world in an effort to bring them back to various departments under the ministry, said Jitendra Singh, minister of state (independent charge) for science and technology.
Deepak Fertilizers plans to revise open offer price to beat Mallya-Poddar efforts
Poddar-Mallya agreement on running MCF likely to be re-worked.
Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
Sebi asked to reconsider open offer nod as KFA was identified as wilful defaulter.
The company recently completed its full integration at the Tirupur unit.
Altaf Ahmed Lal, country head of the US Food and Drug Administration (US FDA) in India, has quit and so have a few other key officials at the American drug regulator's India office.
Sun-Ranbaxy are keen to complete the merger process.
.jpg)
In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.
Mukesh Ambani, the new media mogul of country, has his strategy cut out. For the ETV bouquet of channels, the focus would be the general entertainment channels (GEC).
Today, the company has created a portfolio of vibrant world-class brands.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances